Although LSD1 inhibitors show promising disease modifying activity in clinical trials in chronic-phase MPN [10–12] the successful use of this class of drug in blast-phase will require potent combination therapy approaches. The gene discussed is KDM1A; the disease is myeloproliferative disorder.